# XERS catalysts: Xeris Biopharma Holdings, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/xers/catalysts

> Xeris Biopharma Holdings, Inc. (XERS) has 1 upcoming catalyst. The next is the XP-8121 topline data readout, late 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for XERS?

Xeris Biopharma Holdings, Inc. (XERS) has 1 upcoming catalyst. The next is the XP-8121 topline data readout, late 2028. Press release filed with the SEC (EX-99): "Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030" [Calendar and source filings](https://sec-api.dev/companies/xers/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001867096-26-000077, https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/xers/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Xeris Biopharma Holdings, Inc. |
| Ticker | XERS (Nasdaq) |
| SEC CIK | 1867096 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/xers |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 10, 2019 | [Gvoke Kit (glucagon) FDA approval](https://sec-api.dev/pdufa/glucagon) | XERS |  | completed, approved | "NDA212097 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190910, review_priority STANDARD; sponsor_name XERIS; product GVOKE KIT (GLUCAGON)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212097%22)) |
| Oct 2022 | [XP-8121 topline data readout](https://sec-api.dev/pdufa/xp-8121) | XERS |  | completed, positive | "In October 2022, we reported positive topline Phase 1 data of XP-8121." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000039/xers-20241231.htm)) |
| February 9, 2024 | [Gvoke Kit (glucagon) complete response letter (CRL)](https://sec-api.dev/pdufa/glucagon) | XERS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212097-s012_OtherActionLtrs.pdf%22)) |
| March 6, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL; March 6, 2025 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000034/exh991q42024earningsrelease.htm)) |
| March 14, 2025 | [Gvoke Kit (glucagon) label expansion decision](https://sec-api.dev/pdufa/glucagon) | XERS |  | completed, approved | "NDA212097 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20250314, review_priority STANDARD; sponsor_name XERIS; product GVOKE KIT (GLUCAGON)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212097%22)) |
| May 8, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/exh991q12025earningsrelease.htm)) |
| August 7, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/exh991q22025earningsrelease.htm)) |
| November 6, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL (BUSINESS WIRE); November 6, 2025 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/exh991q32025earningsrelease.htm)) |
| 2026 | [XP-8121 trial start](https://sec-api.dev/pdufa/xp-8121) | XERS |  | scheduled | "We plan to initiate a Phase 3 clinical trial of XP-8121 in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm)) |
| January 8, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL; January 8, 2026 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/pressreleaseissuedbyxerisb.htm)) |
| March 2, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL; March 2, 2026 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/exh991q42025earningsrelease.htm)) |
| May 7, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/exh991q12026earningsrelease.htm)) |
| August 6, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/exh991q22026earningsrelease.htm)) |
| November 5, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000114/exh991q32026earningsrelease.htm)) |
| late 2028 | [XP-8121 topline data readout](https://sec-api.dev/pdufa/xp-8121) | XERS |  | scheduled | "Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm)) |

## Drugs

- [Gvoke Kit (glucagon)](https://sec-api.dev/pdufa/glucagon): 
- [XP-8121](https://sec-api.dev/pdufa/xp-8121): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/xers/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XERS catalysts: Xeris Biopharma Holdings, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/xers/catalysts

```bibtex
@misc{secapidev_companies_xers_catalysts_20261116,
  title        = {XERS catalysts: Xeris Biopharma Holdings, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/xers/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_xers_catalysts_20261116","title":"XERS catalysts: Xeris Biopharma Holdings, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/xers/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
